An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Veltassa

Chemical Namepatiromer
Dosage FormSuspension (oral; 8.4 gm, 16.8 gm, 25.2 gm)
Drug ClassPotassium binders
SystemBlood, Urinary, Digestive
CompanyRelypsa Inc
Approval Year2015

Indication

  • To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Veltassa (patiromer) Prescribing Information2018Relypsa, Inc., Redwood City, CA
Document TitleYearSource
Patiromer for treating hyperkalaemia.2020NICE
Document TitleYearSource
Efficacy and safety of patiromer in hyperkalemia: a systematic review and meta-analysis.2018Journal of Pharmacy Practice
Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia2017Phamacotherapy